Moderna, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
4.2
Underperform
Overall
7.1
Buy
Quality
Health
Growth
Valuation
Sentiment
MRNA
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-145% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $41.42 (-12.0%)
19 analysts
BUY
Target $252.42 (+9.8%)
24 analysts
Fundamentals
MRNA
JNJ
—
Trailing P/E
26.6×
-10.0×
Forward P/E
18.1×
-145.2%
Profit Margin
21.8%
-105.8%
Gross Margin
68.0%
-28.9%
ROE
26.4%
-29.8%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
1.34
Beta
0.33
—
Price / Book
—
$18.7B
Market Cap
$553.3B
$22 – $60
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.